Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

CD19 and CD20 double-target chimeric antigen receptor and application thereof

A chimeric antigen receptor and dual-target technology, applied in the field of biomedicine, can solve problems such as non-expression of tumor antigens, tumor recurrence, and poor therapeutic effect

Pending Publication Date: 2021-04-06
汤朝阳
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, medical diagnosis shows that many tumor cells do not express specific and specific tumor antigens
For example, tumor cells in some hematological tumors do not express CD19 molecules, but express CD20 molecules. Only CAR-T cells targeting CD19 molecules are not effective, and some patients have tumor recurrence after a period of time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CD19 and CD20 double-target chimeric antigen receptor and application thereof
  • CD19 and CD20 double-target chimeric antigen receptor and application thereof
  • CD19 and CD20 double-target chimeric antigen receptor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1 Construction of CAR molecular carrier

[0054] In this example, the coding gene of anti-CD19 and CD20 dual-target chimeric antigen receptor (SEQ ID NO: 6) was firstly synthesized, and restriction endonuclease Pme1 restriction sites were added to the C-terminus and N-terminus of the coding gene. Its protective base and restriction endonuclease Spe1 restriction site and its protective base;

[0055] The coding gene was double digested with restriction enzymes Pme1 and Spe1, and the digested product containing sticky ends was recovered by agar gel electrophoresis, and then ligated into the linearized pWPXLd-eGFP plasmid (containing the same double digested by Pme1 and Spe1). Cohesive ends), the ligation reaction was carried out with the participation of T4 DNA polymerase (Invitrogent) to obtain a lentiviral vector containing the genes encoding the CAR targeting CD19 and CD20 dual targets.

[0056] In this example, the antigen-binding domains of the anti-CD19 scF...

Embodiment 2

[0057] Example 2 Lentiviral Packaging

[0058] In order to introduce CAR molecules into T cells, 293T cells were used to prepare recombinant lentiviruses. When 293T cells were spread to 80-90% of the bottom of a 100mm petri dish, lentivirus packaging was performed:

[0059] 2h before virus packaging, the medium was replaced with DMEM containing 1% fetal bovine serum, and the addition amount was 6mL / 100mm culture dish;

[0060] Prepare the plasmid mixture as shown in Table 1. The pWPXLd-expression plasmid includes a lentiviral vector containing the coding gene of CAR targeting CD19 and CD20 dual targets, and lentivirus containing the coding gene of CAR targeting CD19 single target. Vector, lentiviral vector containing the coding gene of CAR targeting CD20 single target, pWPXLd-eGFP plasmid is an empty vector without CAR coding gene;

[0061] Table 1

[0062]

[0063] Add 36 μg PEI to another 500 μL opti-MEM medium, mix well, and let stand for 5 min at room temperature;

...

Embodiment 3

[0069] Example 3 T cell activation and lentiviral transfection

[0070] Peripheral blood mononuclear cells (PBMCs) were separated from whole blood using Ficoll density gradient centrifugation kit (GE), and after removal of red blood cells, T cells were sorted by MACS Pan-T magnetic beads;

[0071] The sorted T cells were diluted with medium (AIM-V medium + 5% FBS + penicillin 100U / mL + streptomycin 0.1 mg / mL) to a cell concentration of 2.5 × 10 6 pcs / mL for use;

[0072] The CD2 / CD3 / CD28 T cell activation and expansion kit (Miltenyi) was used to activate T cells, that is, the coated magnetic beads were mixed with T cells in a ratio of 1:2, and the final density of T cells was 5×10 6 pcs / mL / cm 2 , after mixing, placed at 37°C, 5% CO 2 Incubator stimulation for 48h;

[0073] 48h after T cell activation, demagnetize beads, centrifuge at 300g for 5min, remove supernatant, resuspend T cells in fresh medium, add CAR-expressing recombinant lentivirus or blank control eGFP lentivi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a CD19 and CD20 double-target chimeric antigen receptor and application thereof. The chimeric antigen receptor comprises an antigen binding structural domain, a transmembrane structural domain and a signal transduction structural domain, wherein the antigen binding structural domain comprises an anti-CD19 single-chain antibody and an anti-CD20 single-chain antibody. The anti-CD19 and anti-CD20 double-target chimeric antigen receptor has targeting activity on CD19 positive and / or CD20 positive cells, T cells expressing the anti-CD19 and anti-CD20 double-target chimeric antigen receptor have killing effect on tumor cells with low CD19 antigen expression quantity or no CD19 antigen expression quantity and tumor cells with low CD20 antigen expression quantity or no CD20 antigen expression quantity, thereby being beneficial to avoiding an immune escape phenomenon, and reducing the possibility of disease recurrence.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and relates to a CD19 and CD20 dual-target chimeric antigen receptor and an application thereof. Background technique [0002] In recent years, with the development of tumor immunology theory and clinical technology, chimeric antigen receptor T-cell immunotherapy (CAR-T) has become one of the most promising tumor immunotherapies. Chimeric antigen receptor (chimeric antigen receptor, CAR) is composed of tumor-associated antigen binding region, extracellular hinge region, transmembrane region and intracellular signal transduction region. Usually, the antibody single-chain fragment variable (single chain fragment variable, scFv) contained in the CAR molecule has a specific binding effect on the tumor-associated antigen (tumor associated antigen, TAA). Cytoplasmic domain coupling. [0003] At present, CAR-T cell therapy has been widely used in the treatment of B-cell malignancies. CAR-T cells t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K19/00C12N15/62C12N15/867C12N5/10A61K39/00A61P35/02A61P35/00
CPCC07K16/2803C07K16/2887C07K14/7051C12N15/86C12N5/0636A61K39/001124A61K39/001112A61P35/02A61P35/00C12N2740/15043C12N2800/107C12N2510/00C07K2317/622C07K2319/03C07K2319/33C07K2319/02C07K2319/74A61K2039/5156A61K2039/804A61K2039/585
Inventor 汤朝阳秦乐吴迪冯世忠冯嘉昆杨乐旋其他发明人请求不公开姓名
Owner 汤朝阳
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com